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10.1  Introduction 
 Irritable bowel syndrome (IBS) is one of the most common gastrointestinal diseases 
in the general population, with a prevalence ranging from 12 % to 30 %, mainly 
affecting younger patients (i.e., <50 years of age) and women [ 1 ]. As in other 
chronic functional gastrointestinal disorders, abdominal discomfort or pain, abnor-
mal bowel habits, and often bloating and abdominal distension are the main clinical 
features. Their diagnosis is based on symptom patterns (i.e., the Rome III criteria), 
which also allow categorization in diarrhea-predominant (D-IBS), constipation- 
predominant (C-IBS), mixed diarrhea and constipation (M-IBS), and unclassifi ed 
(U-IBS) IBS [ 2 ]. Symptom severity ranges from tolerable to severe, both between 
different patients and in the same patient, affecting patients’ quality of life consider-
ably as in some major chronic diseases [ 3 ]. Depending on whether diarrhea or con-
stipation is the predominant disorder, antispasmodics, antidepressants, and 
medications modifying bowel habit represent the main conventional IBS treatments. 
Unfortunately, most patients report long-term inadequacy of current drug therapy 
and a tendency to seek a variety of alternative remedies, especially of a dietary 
nature (up to 65 % of them attribute their symptoms to adverse food reactions) [ 4 ]. 
However, the relationship between IBS symptoms and diet is still controversial, 
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because of research quality and low number of scientifi c studies [ 5 ]. This represents 
a glaring gap that needs to be addressed. 
10.2  IBS Pathogenesis 
 Development and maintenance of IBS symptoms has been attributed to multiple fac-
tors, such as altered small bowel and/or colonic motility (slow, fast, or uncoordinated), 
visceral hypersensitivity (“visceral hyperalgesia”), imbalance in neurotransmitters, 
genetic factors, infections, infl ammation, and psychological dysfunction [ 6 ]. 
 A correlation between IBS and the microorganisms that reside in physiological 
or pathological conditions in the gut has been stressed in some subgroups. In par-
ticular, small intestinal bacterial overgrowth (SIBO) could be responsible for 
increased fermentation and gas production in the small intestine, leading to symp-
toms [ 7 ]. To date authors do not agree on the possible pathogenic mechanisms of 
postinfectious IBS, but the evidence of persistent low-grade mucosal infl ammation 
in some patients could explain how enteric infections affect gut physiology [ 8 ]. 
 Similar histological abnormalities have also been found in colon mucosal biopsies of 
patients with IBS who did not describe any preexisting acute infectious gastroenteritis, 
suggesting a more general “infl ammatory hypothesis” for IBS [ 9 ]. Increased numbers of 
jejunum and terminal ileal mucosa mast cells – a clue for a role for food allergy in an 
IBS subgroup [ 10 ], eosinophils [ 10 ], T lymphocytes (T helper [T H ]2 and T H 17) [ 11 ], B 
lymphocytes, and plasma cells [ 12 ] – characterize this infl ammation. This composite 
infi ltrate interacts with the intestinal nerve plexus and nociceptive structures [ 13 ]. 
Further evidence of the infl ammatory theory of IBS lies in the increased IgE, tryptase, 
eosinophil cationic protein, and eosinophil protein X fecal levels [ 14 ]. Either exogenous 
factors, including food antigens and changes in the resident microbial fl ora, or endoge-
nous chemical irritants, such as bile salts, might be responsible for mucosal infl amma-
tion and local activation of the immune system. In particular, mucosal immune cell 
activation results in changes in the function of submucosal and myenteric neurons, link-
ing these two effector systems in the genesis of gastrointestinal function disorders [ 15 ]. 
 These pathogenic hypotheses might apparently confl ict with the classical one 
that IBS represents a disturbance of the “brain-gut axis.” In this context female gen-
der, family history of IBS, history of physical or sexual abuse, and comorbid psy-
chiatric disorders are strong IBS risk factors [ 16 ]. Some studies sustain that either 
stressful early life events or psychiatric comorbidity or both mediate low-level 
infl ammation as well as lymphocytes and mast cell infi ltration of the bowel. Thus, 
an increasing number of researchers promote the idea of a three-way relationship 
between IBS, mood disturbance, and immune dysregulation [ 17 ]. 
10.3  The Facts: Diet in IBS Patients 
 Most IBS patients assign a signifi cant role to diet in their symptom onset or persis-
tence, and over 60 % of them would like to know what kind of foods should be 
avoided [ 5 ,  6 ]. Unfortunately, only 1–3 % of them are diagnosed as suffering from 
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food allergy using current medical methods. The discrepancy between self-percep-
tion and diagnostic tools is a major source of frustration both for patients and health 
care professionals, who are unable to provide reliable answers and support [ 18 ]. 
Several studies agree that 60 % of IBS patients experience worse symptoms follow-
ing food ingestion, 28 % within 15 min after eating, and 93 % within 3 h. The most 
common foods singled out are wheat products (pasta, bread, pizza), cow’s milk and 
milk-derived products, tomato, eggs, certain meats, fi sh/shellfi sh, cabbage, peas/
beans, onion, hot spices, garlic, apple, peach, citrus, fried food, smoked products, 
fats, food additives, nuts, hazelnuts, chocolate, alcohol, and caffeine [ 14 ,  19 ]. 
 Böhn et al. examined a cohort of 197 adult IBS patients with food allergy/intoler-
ance, IBS symptoms, somatic symptoms, depression and general anxiety, and 
gastrointestinal- specifi c anxiety, using quality of life questionnaires. Eighty-four 
percent of subjects reported symptoms related to at least one food, and over 70 % 
noted symptoms after intake of food items with incompletely absorbed carbohy-
drates (i.e., fermentable oligo-, di-, and monosaccharides and polyols, FODMAPs) 
such as dairy products, beans/lentils, apple, fl our, and plum. Noteworthy, self- 
reported food intolerance was associated with reduced quality of life (sleep, physical 
status, and social interactions) [ 20 ]. A Norwegian population-based cross-sectional 
study reported that 70 % of IBS subjects perceived a food intolerance (mean 4.8 food 
items), 62 % limited or excluded foods from their diet (mean 2.5 food items), and 
12 % drastically modifi ed daily intake causing nutritional defi ciencies in the long run 
[ 21 ]. Data emerging from many studies is the lower consumption of spaghetti, pasta, 
couscous, and rice in IBS than in controls. The fi rst three products are made using 
durum wheat, which tends to be high in gluten and FODMAPs, while the last tends 
to be low [ 22 ]. Similarly, lactose is considered one of the main causes of IBS symp-
toms. Therefore, these patients have a lower consumption of milk and other dairy 
products often self-inducing important nutritional defi cits. Furthermore, IBS patients 
have been reported to have a signifi cantly lower intake of retinol (vitamin A) equiva-
lent, β-carotene, and magnesium, due to a lower consumption of certain vegetables 
(tomatoes, raw vegetables, etc.). Controversially, they report a higher consumption 
of pears, peach, grapes, melon, mango, and plums, which are rich in FODMAPs and 
documented as possible trigger factors of symptoms [ 22 ]. 
 Finally, 12 % of IBS patients either limit or avoid alcohol intake due to self- 
reported intolerance [ 19 ]. 
 In conclusion, IBS patients try to avoid certain food items rich in gluten and 
FODMAPs, even though the higher consumption of some FODMAP-rich fruits and 
vegetables remains questionable. The total calories, carbohydrates, proteins, and fat 
intake does not seem to differ from the general population, but such dietary restrictions 
could be responsible for their low calcium, phosphorus, vitamin B2, and vitamin A intake. 
10.4  A Possible Role for Food Allergy and Intolerance 
 The large amount of evidence on dietary components causing IBS symptoms has 
not clarifi ed the possible pathogenic mechanisms underlying this relationship. 
Physicians have suggested a possible role for food allergy or food intolerance. 
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“Food allergy” (or sensitivity or hypersensitivity) is defi ned as “reproducible 
adverse reaction arising from specifi c immune responses occurring on exposure to 
specifi c food antigens.” Whenever similar reactions occur without evidence of 
immunological mechanisms, they are named “food intolerance” [ 23 ]. 
 The role of IgE-mediated and non-IgE-mediated allergic response in IBS has 
been studied for a long time, producing only confl icting data and no consistent evi-
dence. The fi rst studies evaluated that possible association are from the mid-1980s, 
but several have been conducted more recently [ 5 ,  24 ]. The results of these recent 
studies are reported in Tables  10.1 and  10.2 . Authors mainly focused on the conven-
tional methods (total serum IgE test, skin prick test (SPT), radioallergosorbent test 
(RAST), search for IgE fragment crystallizable (FC) in fecal extracts, elimination 
diets, and rechallenges) to diagnose IgE-mediated allergies in patients reporting 
IBS-like symptoms [ 5 ,  25 ]. The main discrepancy found in these studies is between 
self-perceived food intolerance and the positive results of diagnostic tests [ 25 ]. Two 
hypotheses were proposed to explain these results: (1) low serum-specifi c IgE levels 
and (2) inadequate allergenic preparations used for SPT and ImmunoCAP. These 
hypotheses would explain the low prevalence of wheat IgE-mediated enteropathy, 
including food allergy in IBS patients [ 26 ].
 Inadequacy of the conventional methods (SPT and serum food allergen-specifi c 
IgE levels) to identify IgE-mediated responses in IBS patients led us to evaluate the 
effi cacy of fl ow cytometric cellular allergen stimulation test (FLOW-CAST) in the 
diagnosis of food allergy in 120 consecutive IBS patients [ 27 ]. We concluded that 
this diagnostic test might supplement or better replace routine allergy tests [ 27 ]. 
 The substantial lack of agreement on the role of typical IgE-mediated allergic 
reactions in IBS pathogenesis has led physicians to explore alternative hypotheses. 
In particular, hypersensitivity reactions induced by a different antibody class (i.e., 
IgG) seem to be of some importance (Table  10.3 ).
10.4.1  IBS and Food Intolerance 
 Other physicians instead focused nonimmunologic responses to food antigens (i.e., 
food intolerances), but questionable outcomes have been seen both due to issues 
surrounding diagnostic tools and diffi culties in projecting well-designed dietary tri-
als. Triggers for symptom onset or worsening have been historically identifi ed in 
caffeine, alcohol, fi ber, and fats, although strong evidence is confl icting in some and 
lacking in most. Correct identifi cation of symptom-inducing foods is diffi cult to 
achieve both because meals are complex mixtures of dietary components and the 
timing of symptom onset can vary, both with different foods and with the same food 
in different patients [ 19 ]. However, most evidence identifi es foods as the triggering 
factors of symptom onset rather than as a cause of the condition [ 28 ]. 
 The role of dietary components in inducing IBS symptoms has been better 
explored, with some studies reporting how certain food components can contribute 
to causing carbohydrate malabsorption [ 28 ,  29 ]. In the last decade, several authors 
have approached the study and management of suspected food intolerance in IBS, 
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looking at FODMAPs with increasing interest, focusing on the effects of a low 
FODMAP diet [ 28 ,  30 – 34 ]. More recently, a new clinical entity – non-celiac gluten 
sensitivity (NCGS) – has burst into this complex “world,” and it has been sug-
gested that it may be important in a subgroup of IBS patients [ 35 – 37 ], although 
contradictory data seem to deny the role of a gluten-free diet in the treatment of 
these patients [ 38 ]. 
10.5  What Are FODMAPs? 
 Several studies have explored the changes in dietary composition during the last 
few decades, in particular how it could have been modifi ed by urbanization. 
Reports confl ict about whether sugar intake has increased, but agree on the same 
focus point: the proportion of sugar intake made up of fructose is increasing. In 
this context, the intakes of fruit juices as well as the use of high-fructose corn 
syrup (which contains 42–55 % fructose) as sweeteners in many manufactured 
foods seem to play the leading role [ 39 ]. However, no direct studies of time trends 
in fructan ingestion are available, but indirect evidence indicates changes in their 
consumption patterns. Pasta and pizza intake, major sources of fructans, has 
increased exponentially, and at the same time, the type of fructans in the diet is 
changing. Similarly, even if no direct data is available about intake of polyols, it 
is likely that their use as food additives to produce “sugar-free” products has led 
to increased consumption [ 39 ]. 
 Poorly absorbed, short-chain carbohydrates and polyols (lactose, fructose, and 
sorbitol) were tested throughout the 1980s and 1990s (especially observational 
cohort studies), to identify their role as symptom inducer in functional bowel disor-
ders and IBS. Authors agree they act in a dose-dependent manner and that a dietary 
restriction of all three together could bring symptomatic relief [ 30 ,  31 ,  34 ]. However, 
international literature about the biochemistry and physiology of digestion denotes 
how other carbohydrates are involved in IBS-like symptom onset. Fructo- 
oligosaccharides (fructans or FOS) and galacto-oligosaccharides (galactans or 
GOS) are short-chain carbohydrates incompletely absorbed in the human gastroin-
testinal tract. In particular, patients report worsening of symptoms whenever these 
sugars are consumed in combination (e.g., lactose with fructans, fructose with sor-
bitol, etc.), indicating their additive effects [ 33 ,  40 ]. Other potential culprits seem to 
be incompletely absorbed polyols, i.e., mannitol, maltitol, and xylitol, used as arti-
fi cial sweeteners, but also found naturally in foods [ 41 ]. In 2005, a team of Australian 
researchers theorized that foods containing these poorly absorbed, short-chain car-
bohydrates worsen the symptoms of some digestive disorders and coined the acro-
nym FODMAPs, grouping them all together according to their chain length [ 42 ]. 
Characteristics shared by all these short-chain highly osmotic carbohydrates are the 
poor absorption in the small intestine and the rapid fermentation by gut bacteria. 
These specifi c features are responsible for increased gas production, bowel disten-
sion, bloating, cramping, and diarrhea – all symptoms of IBS, triggered in associa-
tion with intrinsic visceral hypersensitivity [ 43 ]. 
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 FODMAP intake varies across ethnic and dietary groups due to different dietary 
behavior. Fructose and fructans are most widespread in the North American and 
Western European diets; therefore, they should be considered the ones to which 
nearly all patients with IBS are exposed in their everyday diet. 
10.6  Possible Mechanisms of FODMAP Triggering of IBS 
Symptoms 
 How FODMAPs exert their effects on IBS patients is still uncertain, but some 
researchers are studying the matter. The poor absorbability of FODMAPs in the 
small intestine has been considered a possible starting point, as shown using an ileos-
tomy model. Carbohydrates increase water content in the output from the stoma, 
mainly because of an osmotic effect. This effect could easily explain diarrhea in 
some individuals [ 29 ]. Undseth et al. used magnetic resonance imaging to study the 
osmotic effect of FODMAPs by the analysis of small bowel water content (SBWC). 
Fructose, lactulose, inulin, or mannitol meals but not a glucose meal increase water 
content in patients suffering from D-IBS but not in healthy volunteers [ 44 ]. 
 Other authors focused on gas production after FODMAP fermentation in the gut. 
Ong et al. designed a single-blind, crossover, short-term, interventional study to 
assess gas production during low and high FODMAP diets in IBS patients and 
healthy volunteers. The high FODMAP diet produced higher levels of breath hydro-
gen in both groups; interestingly, IBS patients were found to have higher levels 
during each dietary period than the controls. The latter reported just increased fl atus 
production on a high FODMAP diet, whereas IBS patients complained of rapid 
onset of gastrointestinal symptoms and lethargy. Conversely on a low FODMAP 
diet, breath hydrogen production (and consequently symptom score in IBS patients) 
was reduced both in healthy volunteers and in patients. This study confi rms the 
additive bacterial fermentative nature of the short-chain carbohydrates (with pro-
duction of short-chain fatty acids [SCFA], including butyrate, and gases such as 
carbon dioxide, hydrogen, and in some people methane) and their role in causing 
gastrointestinal symptoms [ 33 ]. In the context of bacterial fermentation, Brighentini 
et al. found that the speed of hydrogen production is inversely proportional to 
FODMAP chain length [ 45 ], and Clausen et al. indicated the fermentative rather 
than osmotic effect of short-chain carbohydrates after entering the colon [ 46 ]. 
 Another research line points to FODMAP effects on gastrointestinal motility [ 47 ]. To 
assess such effects on gastrointestinal motility, Madsen et al. evaluated 11 healthy vol-
unteers in a double-blind crossover investigation. The subjects ingested a glucose solu-
tion or a mixture of fructose and sorbitol, in random order, marked with (99m)
Tc-diethylenetriaminepentaacetic acid. The mouth-to-cecum transit of the radiolabeled 
marker was faster, and the percentage content of the marker in the colon was higher after 
ingestion of the fructose-sorbitol mixture than after ingestion of glucose [ 48 ]. Both the 
osmotic effect of FODMAPs and a contemporary activation of neural feedback path-
ways and/or hormonal changes from SCFA production, secondary to FODMAP bacte-
rial fermentation, might be responsible for this increased gut motility [ 49 ]. 
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 In addition, in animal models (rats), fructo-oligosaccharides were responsible for 
injury of the colonic epithelium and increased intestinal permeability [ 50 ]. 
 FODMAP ingestion effects go beyond the gastrointestinal tract, being responsi-
ble for systemic effects. Mild depression has been reported in women with IBS, 
after fructose and lactose intake [ 51 ], improving when free fructose is eliminated 
from the diet. 
 FODMAPs also affect the intestinal fl ora of these patients. Patients with IBS have 
fewer  Lactobacillus spp. and  Bifi dobacterium spp. in their intestinal fl ora than healthy 
individuals. These bacteria bind to epithelial cells, inhibit pathogen adhesion, and 
enhance barrier function; in addition, they do not produce gas upon fermenting carbo-
hydrates, an effect which is amplifi ed as they also inhibit  Clostridium spp. growth. 
Bacteria such as  Clostridium spp. break down FODMAPs, induce gas production, and 
cause large intestine distension, with abdominal discomfort and pain [ 52 ]. 
 All this evidence could lead us to think that all the different carbohydrates mak-
ing up the large family of FODMAPs have similar physiological effects and there-
fore should be considered together. That is true only to a limited extent. Although 
all exert an osmotic effect, this varies according to the molecular weight and rapid-
ity of absorption of the specifi c carbohydrate. Absorption across the small intestinal 
wall varies according to the dose and speed of intestinal transit and for fructose the 
luminal glucose content (glucose facilitates fructose absorption) and individual 
absorptive capacity via fructose-specifi c transporters. Thus, fructose and polyols 
have a greater osmotic effect than fructans and galacto-oligosaccharides, whereas 
their luminal concentration will fall more distally because of their slow absorption 
as opposed to no absorption for oligosaccharides. Conversely, oligosaccharides will 
have greater fermentative effects since they are not absorbed [ 53 ]. 
 These hypotheses are consistent with current knowledge of IBS pathogenesis, 
among which, visceral hypersensitivity is the most important. Gut distention, due to 
increased gas production and other mechanisms, abnormally stimulates the enteric ner-
vous system, which reacts by altering its motility patterns. The brain analyzes such 
changes and interprets them as bloating, discomfort, and pain. Dietary components that 
could stimulate this mechanism should have the following features: (a) poorly absorbed 
in the proximal small intestine, (b) composed of small molecules (i.e., osmotically 
active), (c) rapidly fermented by bacteria (potentially they should be fermented both by 
small intestinal and cecal bacteria, expanding, at the same time, the bacterial popula-
tion, i.e., a “prebiotic” effect), and (d) associated with hydrogen production. All these 
seem to describe dietary FODMAPs. In others words, to better highlight an abovemen-
tioned concept, FODMAPs do not cause IBS [ 30 ], but represent possible triggers for 
symptom onset, and their intake reduction might reduce patient complaints. 
10.7  Low FODMAP Diet Benefits for IBS Patients 
 Diets based on fructose, with or without sorbitol, and lactose restriction, have been 
used for a long time, in the management of patients suffering from functional gut 
symptoms and IBS. Unfortunately, confl icting results have been reported in 
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literature [ 30 ,  31 ,  34 ]. The very limited success of this approach is the probable 
cause of the slow spread of this kind of diet. Noteworthy, limited FODMAP restric-
tion ignores the evidence that there is potentially a great amount of FODMAPs in 
the everyday diet, all of which have similar end-effects in the bowel. Recently, 
authors have embraced the “FODMAP concept” or approach: a global FODMAP 
restriction should have a far greater and more consistent effect than a limited one. 
Thus, reduction of the intake of all poorly absorbed short-chain carbohydrates 
should be more effective in preventing luminal distension (and consequently symp-
tom onset) than merely concentrating on one of these [ 54 ]. 
 A research trial designed as a retrospective uncontrolled audit by Shepherd et al. 
was the fi rst to confi rm the role of a low FODMAP diet in managing gastrointestinal 
complaints. Patients with IBS and fructose malabsorption underwent a low fructose/
fructan (and polyol, if the patients noted symptom induction) diet. Seventy-four 
percent of patients reported abdominal symptom improvement, with a durable effi -
cacy closely related to dietary compliance. However, this study suffers from a sig-
nifi cant weakness in its retrospective approach that greatly undermines its reliability, 
especially in a fi eld where “placebo effect” is particularly widespread [ 34 ]. To 
resolve this issue and prove the effi cacy of a low FODMAP diet, the same author 
designed a randomized, double-blind, placebo-controlled, quadruple arm crossover, 
rechallenge trial with fructose, fructans, fructose plus fructans, and glucose (as pla-
cebo) at varying doses (low, medium, or high). Twenty-fi ve patients with IBS, who 
had documented fructose malabsorption as well as a previously demonstrated dura-
ble (3–36 months) symptomatic response to reduction of dietary FODMAPs, were 
enrolled in the study. Abdominal symptoms recurred in 70–80 % of patients, in a 
dose-dependent way, when fed with pure forms of FODMAPs, especially with fruc-
tose plus fructans; this proved an additive effect, especially if compared to 15 % 
complaining of the same abdominal symptoms when fed a similar diet spiked with 
placebo [ 28 ]. Although conducted according to the strictest scientifi c rules, this 
study has the weakness of being carried out in a single center in Australia. This 
specifi c feature has made other studies necessary to confi rm these preliminary 
observations. 
 In 2012, Staudacher et al. performed a randomized, controlled, non-blinded trial 
in 41 United Kingdom patients with IBS. Physicians investigated the effects of fer-
mentable carbohydrate restriction on gastrointestinal symptoms, luminal microbi-
ota, and SCFA. Patients were randomly assigned to intervention diet or habitual diet 
group for 4 weeks. Patients in the intervention group more frequently reported 
symptom reduction compared with controls. In addition, even though the total lumi-
nal bacteria at follow-up did not differ between groups, when adjusted for baseline, 
the intervention group had lower concentrations of bifi dobacteria. Finally, no differ-
ence in total or individual fecal SCFA could be found between groups. Unfortunately, 
this study also had several other weaknesses: small sample size, use of a “habitual” 
diet, which varied from patient to patient, the lack of a standardized low FODMAP 
diet, and differences in patient-provider contact time [ 40 ]. In 2014, going back to 
Australia, a randomized, placebo-controlled, single-blind, crossover study, evalu-
ated the effect of different diets in a group of 30 patients with IBS and 8 healthy 
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individuals. Subjects were randomly assigned to groups receiving 21 days of either 
a diet low in FODMAPs or a typical Australian diet, followed by a washout period 
of at least other 21 days, before crossing over to the alternate diet. IBS patients 
effectively reduced symptoms on the low FODMAP diet. Noteworthy, with no dif-
ference in IBS subgroup, patients reported the greatest symptom improvement 
within the fi rst 7 days. No signifi cant changes were found between diets in healthy 
controls. Although better designed than prior studies, the crossover design, the use 
of a “typical” Australian diet, and the small sample size make it diffi cult to apply the 
results of this study to all IBS patients [ 32 ]. In the same period, Pedersens et al. 
conducted a randomized, controlled, unblinded trial in 123 IBS patients [ 55 ]. 
Patients underwent one of the following diets for 6 weeks: low in FODMAPs, high 
 Lactobacillus rhamnosus GG, and a normal Danish/Western diet. At week 6, a sta-
tistically signifi cant reduction in the IBS severity score system was observed in the 
low FODMAP group and  Lactobacillus rhamnosus GG group compared to the nor-
mal Danish/Western diet group. However, adjusted linear regression analysis 
showed a statistically signifi cant improvement of IBS severity score in the low 
FODMAP diet group vs. normal Danish/Western diet group, but not in  Lactobacillus 
rhamnosus GG group vs. normal Danish/Western diet group. Finally, quality of life 
was not signifi cantly altered in any of the three groups. Analysis of IBS subgroups 
showed the results were signifi cant for the D-IBS and M-IBS subtypes, but not for 
the C-IBS subtype, in both low FODMAP and  Lactobacillus rhamnosus GG treat-
ment groups. The unblinded design and absence of both a placebo capsule group 
and a standardized preprepared low FODMAP diet make it diffi cult to interpret this 
study [ 56 ]. 
 Other studies comparing effects of a low FODMAP diet to normal diets are 
reported in Table  10.4 .
10.8  Diagnosis of FODMAP “Malabsorption” 
 The clinical and pathophysiological features of FODMAPs are not yet clear, and the 
diffi culty of establishing a diagnosis of FODMAP malabsorption is even more try-
ing. Usually, after an accurate clinical history, including dietary and lifestyle assess-
ment, with a focus on potential food intolerance, patients undergo clinical 
investigations in accordance with local/national guidelines. The most frequently 
required investigations are blood and fecal tests, endoscopy and/or radiological 
imaging to rule out any organic disease. In the absence of organic disease or food 
allergy, patients are diagnosed as suffering from a functional gastrointestinal disor-
der. Unfortunately to date diagnosis of food intolerance in most areas is still impos-
sible, and only a few tests are clinically useful to identify specifi c food intolerance. 
Breath hydrogen levels provide a reliable measure of sugar absorption. A signifi cant 
rise in breath hydrogen following test sugar intake demonstrates poor absorption 
with subsequent fermentation by intestinal microfl ora [ 57 ]. Positivity to a breath 
test could allow the identifi cation of carbohydrates responsible of symptom onset 
and whose exclusion from the diet could reduce intestinal discomfort. In contrast, a 
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negative breath test proves complete absorption of the sugar suggesting that intake 
of that specifi c carbohydrate should not infl uence patient symptoms. Therefore, 
breath hydrogen testing to defi ne absorption of a fructose and/or lactose load is very 
useful as it can reduce the extent of the necessary dietary restriction [ 57 ]. Routinely, 
to diagnose FODMAP malabsorption, fructose (testing dose of 35 g), lactose (test-
ing dose of 25–50 g), and sorbitol (testing dose of 10 g) breath tests are performed. 
Nevertheless, physicians should remember that there are three other FODMAPs 
(fructans, galactans, and mannitol) acting as potential triggers of IBS symptoms. No 
specifi c breath test is available for fructans and galactans, since they are always 
malabsorbed and fermented, whereas mannitol breath test is rarely performed, as it 
is not a widespread component in the diet and can be investigated as a trigger 
through simple dietary elimination and rechallenge [ 57 ]. 
 However, breath tests have a moderate degree of false positivity. As an example, 
IBS patients suffering from SIBO, diagnosed by lactulose breath test, a reliable and 
noninvasive test for the diagnosis of this condition, might have falsely abnormal 
breath tests for fructose, lactose, and sorbitol [ 58 ]. 
10.9  Tables of the FODMAP Content of Foods: Strengths 
and Weaknesses 
 A number of studies offer more specifi c knowledge about food composition, in 
particular, FODMAP content, which allows us to better modify the dietary regimens 
of IBS patients. The broader range of FODMAPs, including FOS, GOS, and man-
nitol, in addition to fructose, lactose, and sorbitol, forces us to avoid all these carbo-
hydrates in low FODMAP diets, with elimination of an extended spectrum of foods. 
Such large restrictions are required to publish tables of food composition on fruits, 
vegetables, breads, and cereals [ 59 ]. The impact of dietary modifi cation of 
FODMAPs can have on functional gut symptoms should shift the focus to the pos-
sibility of simply and accurately assessing FODMAP intake in individuals and spe-
cifi c populations. In this context, administration of food frequency questionnaires 
(FFQs) is a simple and useful assessment. The Monash University Comprehensive 
Nutrition Assessment Questionnaire (CNAQ), a 297-item comprehensive, semi-
quantitative FFQ, has shown its effi cacy in estimating intake of macro- and micro-
nutrients, FODMAPs, and glycemic index/load, in an Australian population. Barret 
et al. validated this FFQ proving how this tool allows patients to identify a wide 
range of low FODMAP foods and manage their IBS with less restrictive diets [ 60 ]. 
 One of the most important limits to the spread of a low FODMAP diet is the 
development of tables assessing FODMAP-rich and FODMAP-poor foods. To date, 
published lists of food composition report only a limited description of FODMAP 
content. The recent development of FODMAP content measuring methodologies, 
together with a systematic examination of fruits, vegetables, and cereals, partially 
overcome this issue. However, the strongest limitation is the absence of a unique 
and widely approved cutoff level indicating a food as “high” or not in FODMAPs. 
This is further complicated by the direct relationship between the total amount of 
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FODMAPs ingested and whether symptoms will be induced or not. Several studies 
have tried to assess possible cutoff levels to avoid symptom induction [ 34 ,  59 ]. The 
preliminary results hint that the total dose for therapeutic benefi t in IBS population 
should be less than 0.5 g FODMAPs per sitting or less than 3 g FODMAPs per day. 
Unfortunately, CNAQ showed that these values are considerably lower than the 
amount obtainable through a strict diet [ 34 ]. 
10.10  Practical Low FODMAP Diet Management 
 The effi cacy shown by a low FODMAP diet allows its use as a potentially effective 
treatment option for IBS patients, under the monitoring of an expert dietitian. A 
preliminary step, because of the variability of response to diet and the possible 
coexistence of a food allergy, is to identify the predictors of both of these different 
conditions. Reports of atopic history, symptoms related to mast cell activation, or 
concurrent systemic manifestations, such as urticaria or asthma, should direct our 
focus to an IgE-mediated food allergy. 
 Considering the different nature of each FODMAP, it is not surprising that not all 
of these carbohydrates will be symptom triggers for all patients. Malabsorbed 
FODMAPs due to altered gut fl ora, visceral hypersensitivity, and motility disorders, 
typical of IBS patients, are the ones most likely to play a major role in inducing 
symptoms [ 33 ]. Noteworthy, fructans and galactans are always malabsorbed and 
fermented by intestinal microfl ora. The remaining FODMAPs will induce symp-
toms only in the proportion of IBS patients that malabsorbs them. In this regard, 
lactose and fructose malabsorption in white IBS patients is estimated to be 25 % and 
45 %, respectively [ 30 ]. Finally, polyols are incompletely absorbed, but their low 
amounts found naturally in foods as well as in sugar-free products and medications 
is usually well tolerated in most people [ 30 ]. 
 Breath tests should be considered useful diagnostic tools helping physicians to 
implement personalized specifi c low FODMAP diet, but they cannot be considered 
mandatory. Where breath tests cannot be performed, a trial of a full low FODMAP 
diet can be conducted, followed by challenge with each carbohydrate (fructose, 
lactose, sorbitol, and mannitol) initially avoided. As a fi nal step, small amounts of 
fructans and galactans may be tested to assess the level of tolerance, even though 
they are associated with gas-induced symptoms, even in healthy subjects [ 33 ]. 
 Nowadays, the low FODMAP diet has been mainly evaluated as a dietician- 
delivered diet. A one-to-one patient-dietitian setting, together with the use of writ-
ten educational material and recipe books, has been used, but some group education 
sessions have been tested with apparent success and cost reduction [ 61 ]. 
 Noteworthy, some patients report using instructions and diet sheets by them-
selves to manage their symptoms. Physicians should be cautious of this approach, 
discouraging patients to continue without a dietician’s consultation, due to the lack 
of suffi cient ad hoc studies and the possible dietary self-induced imbalance. Rao 
et al. tried to create a systematic approach to patients at the fi rst consultation. (1) 
Defi ne patient’s lifestyle and alimentary behavior. Physicians should address 
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patients with direct questioning and ask them to compile pre-completed food record 
diaries (for at least a 7-day period). This approach allows the identifi cation of daily 
FODMAP intake. (2) Explain the scientifi c basis of FODMAP physiopathology in 
IBS. Patients must be aware of the role of FODMAPs to increase the likelihood of 
lasting diet compliance. (3) Provide specifi c dietary instructions. (4) Discuss tech-
niques to avoid unintentional FODMAP intake. Patients often report great diffi culty 
handling situations where food preparation cannot be controlled. (5) Instruct 
patients about the need for a strict and long-term diet. Patients sensitive to FODMAPs 
often observe symptom improvement within the fi rst week of a restricted diet. 
However, it has been found that there is a clear increase in effi cacy over the fi rst 
6 weeks, so it is recommended to attempt strict adherence for at least 6–8 weeks. If 
the diet has shown little effi cacy after 8 weeks, it may be discontinued [ 62 ]. 
 These preliminary steps allow physicians to assess symptom response on a strict 
FODMAP diet. Obviously such a limited diet cannot be continued for long; thus, it 
should be a must to defi ne individual tolerance. Single carbohydrate reintroduction 
allows this process ensuring maximum variety in the diet, to avoid overrestrictions 
and reduce the risk of nutritional inadequacy. Rechallenge must be taken separately 
for each carbohydrate with food as simple as possible to avoid overlaps. Whenever 
patients report inadequate response to the diet, specifi c questioning is required to 
determine the adherence and modify any defi ciency. If adherence is indicated, atten-
tion should be paid to reduce intake of resistant starch and both insoluble and solu-
ble fi ber [ 43 ]. 
 Adherence to a low FODMAP diet has been found to be relatively high, in par-
ticular after adequate instruction. Unwillingness to undertake dietary recommenda-
tions, diffi culties accessing and increased expense of wheat-free foods, and dislike 
of the taste represented the main barriers to adherence [ 34 ]. 
10.11  Limitations and Potential Concerns of the Low FODMAP 
Diet in IBS Patients 
 The presented data show that a low FODMAP diet could lead to symptom control 
in specifi c subclasses of IBS patients, but it is far from being effective in all of them. 
Foods represent just the trigger of symptom onset, and since diets do not infl uence 
the pathophysiological substrate of IBS, intermittent symptoms remain in many 
patients, albeit at a tolerable level [ 32 ]. 
 Requiring further and better defi nition is the security of long-term low 
FODMAP diets; such a restrictive diet is at risk of being nutritionally inadequate. 
In this context, some preliminary data come from Staudacher et al. who reported 
that a strict 4-week-long low FODMAP diet reduced total carbohydrate intake, 
including both total sugars and starches; however, total energy, protein, fat, and 
non-starch polysaccharide levels did not change. In addition, authors found a 
reduction of total calcium intake in patients following a restricted diet for more 
than 4 weeks [ 40 ]. However, a restricted low FODMAP diet should not compro-
mise nutritional adequacy, eliminating whole categories of food. Expert dietician 
10 From Food Map to FODMAP in Irritable Bowel Syndrome
160
consultation is important in food substitution with suitable alternatives from the 
same food group. The greatest diffi culties are with legumes (including chickpeas, 
baked beans, red kidney beans, and lentils), since these all contain fructans and 
galactans. Fortunately, in a low FODMAP diet, foods such as seeds, nuts, and 
quinoa are encouraged, as well as eating legumes in small amounts [ 43 ]. As 
reported by Staudacher et al. [ 40 ], reduction in fi ber intake might be a conse-
quence of the restriction of wheat-based products, so patients should be advised, 
as part of dietary counseling, to ensure adequate intake of resistant starch and 
non-starch polysaccharides. In addition, FODMAPs (particularly oligosaccha-
rides, such as inulin) are prebiotic, increasing growth of bacteria with known 
health benefi ts (especially  Bifi dobacterium spp.), and precursors for SCFA pro-
duction, known to be important for colonic health. Thus, it is likely that a low 
FODMAP diet would counteract the prebiotic actions of FODMAPs and reduces 
SCFA production [ 59 ]. In this context, 26 IBS patients and 6 healthy subjects 
were randomly allocated in one of two dietetic regimens differing only in 
FODMAP content and then crossed over after a washout period. Participants col-
lected a 5-day fecal sample during their habitual diet and after 17 days of a low 
FODMAP diet and Australian diet. Analysis of stool found greater microbial 
diversity, reduced total bacterial abundance, higher fecal pH, but similar SCFA 
concentrations during the low FODMAP diet compared with the Australian diet. 
Prebiotic bacteria, namely,  Bifi dobacterium spp., concentrations were similar in 
the two diets, but total bacterial abundance decreased on low FODMAP diet. On 
the contrary, the Australian diet increased relative abundance of butyrate-produc-
ing  Clostridium cluster XIVa and mucus degrading-associated  Akkermansia 
muciniphila and reduced mucus degrading-associated  Ruminococcus torques . 
This study indicates that FODMAP reduction is not “antiprebiotic.” Noteworthy, 
even if no reduced prebiotic effect by FODMAPs was found, there was a reduc-
tion in total bacterial abundance. The functional and health implications of such 
changes need further studies, to exclude possible adverse effects in the long term 
[ 63 ]. Hence, it is important to emphasize that patients receiving this dietary 
restriction should be monitored for long-term effects on health, and more data are 
needed regarding benefi ts vs. harms [ 58 ]. 
 For all the abovementioned reasons, a strict long-term low FODMAP diet must 
be discouraged. Reintroduction of FODMAP foods should be instituted as soon as 
possible after achieving a good symptomatic response. This will allow identifi cation 
of the cutoff level of food restriction that each patient requires to adequately control 
symptoms without encountering nutritional imbalances [ 42 ]. 
10.12  IBS and NCGS 
 Having assessed the role of food as a possible trigger for symptom onset in IBS 
patients, we must recognize a role of primary importance for wheat, the basis of 
most popular diets in the Western world [ 35 – 37 ,  64 ]. Several reasons have been 
proposed to explain its role as symptom inducer: (1) high fructans content, as 
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member of the family of FODMAPs; (2) autoimmune disorder trigger; and (3) high 
IgE and non-IgE-mediated allergenicity. 
 Extending the perspective over the longtime encoded disorders, researchers’ 
attention is shifting to non-celiac gluten sensitivity (NCGS) [ 65 ]. 
 The NCGS is a syndrome characterized by intestinal and extraintestinal symp-
toms related to the ingestion of gluten-containing food, in subjects that are not 
affected by either celiac disease (CD) or wheat allergy (WA) [ 37 ,  64 ,  65 ]. In 2013, 
Biesiekierski et al. tested 37 subjects with IBS, based on Rome III criteria, and 
NCGS. Authors aimed to investigate if IBS symptoms were related to gluten intake 
rather than FODMAPs. Participants were randomly assigned to groups given a 
2-week gluten-free and reduced FODMAP diet and were then placed on a high- 
gluten diet (16 g/day), a low-gluten diet (2 g/day), or placebo diet (no gluten), for 
1 week. After a washout period of at least 2 weeks, patients were randomized to the 
second arm and, then, again after a 2-week-long washout period, to the third arm. 
During the diet challenges, a visual analogue scale was used to assess symptoms. 
Twenty-two participants then crossed over to groups given gluten or control diets 
for 3 days. In all participants, gastrointestinal symptoms consistently and signifi -
cantly improved during reduced FODMAP intake, but signifi cantly worsened when 
their diets included gluten or whey protein. However, gluten-specifi c effects were 
observed in only 8 % of participants, and the worsening of symptoms across dietary 
arms was thought to be due to stress put on the patients due to the need for frequent 
clinic visits rather than due to diet differences [ 38 ]. According to these results, the 
authors concluded that NCGS does not exist and that the symptoms in the self- 
reported gluten-sensitive patients were due to the FODMAP content in the wheat. 
However, looking at the study’s supplemental fi le, it emerged that among 149 
patients initially recruited, only 40 were included in the study, and more than two- 
thirds of the patients were excluded since they had the DQ2 or the DQ8 alleles or an 
increase in duodenal mucosa lymphocytes. It is well known that both of these are 
very frequent characteristics in NCGS patients. By excluding these patients, the 
Australian colleagues introduced a selection bias, and we suggest that they have 
studied another kind of NCGS patients, preselecting only those without any immu-
nologic activation [ 38 ]. 
 In NCGS, patients complain of IBS-like symptoms, often related to extraintesti-
nal manifestations, which disappear on a gluten-free diet. This evidence, however, 
has not eliminated all doubts about what is actually responsible for the clinical 
manifestations of this new disease (gluten or other components of wheat), thus we 
suggested the term “non-celiac wheat sensitivity” (NCWS) [ 66 ]. With a prevalence 
ranging from 0.55 % to 6 % of the general United States population, NCWS repre-
sents an extremely widespread problem [ 65 ]. Usually, it affects females (male to 
female ratio ranging between 1:2.5 and 1:4) [ 37 ,  65 ] in the third-fourth decades of 
life [ 37 ]. 
 Unfortunately, to date physicians have not managed to identify a specifi c marker 
for this disease, so it is mainly defi ned by “negative” criteria: (1) lack of the key CD 
criteria (e.g., autoimmunity and histology), (2) no evidence of IgE-mediated wheat 
allergy, and (3) response to wheat elimination diet (implemented in a blinded fashion 
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to avoid a possible placebo/nocebo effect) [ 64 ,  67 ]. Clinical manifestations usually 
occur soon after wheat ingestion, improving or disappearing (within hours or few 
days) on gluten elimination diet and relapsing following its reintroduction. 
Gastrointestinal disorders and systemic manifestations are complexly weaved in 
NCWS, but they can also occur separately [ 36 ,  64 ]. Gastrointestinal involvement con-
sists of IBS-like symptoms, such as abdominal pain, bloating, and bowel habit abnor-
malities, whereas systemic manifestations are extremely variable: fatigue, foggy 
mind, headache, depression, joint and muscle pain, leg or arm numbness, dermatitis 
(from skin rash to eczema), anemia, and several others [ 37 ,  65 ]. The very frequent 
presence of extraintestinal symptoms is an important argument to exclude FODMAPs 
as the cause of NCGS. Furthermore, as a confi rmation of a prevalent or exclusive 
immunologic pathogenesis of NCGS, there is the recent evidence that higher propor-
tions of patients with NCWS develop autoimmune disorders (mainly Hashimoto’s 
thyroiditis), have an elevated frequency of antinuclear antibodies (ANA) in the serum, 
and showed DQ2/DQ8 haplotypes compared with patients with IBS [ 68 ]. 
 In any case, NCWS pathogenesis is still largely undetermined and debated [ 64 ]. 
Proposed pathogenic mechanisms are (1) non IgE-mediated wheat allergy [ 37 ,  65 ], 
(2) activation of the innate immunity mechanisms by amylase-trypsin inhibitors 
(ATIs) [ 65 ], and (3) gastrointestinal neuromuscular abnormalities induced by the 
gliadin, leading to smooth muscle hyper-contractility and indirectly to increase in 
luminal water content [ 69 ]. At the current level of knowledge, researchers agree that 
there is a reasonable overlap between NCWS and IBS, and NCWS and IBS patients 
might easily crossover. 
10.13  Low FODMAP Diet or Gluten-Free Diet in NCWS? This Is 
the Question 
 The coexistence of gluten and fructans in wheat has recently raised the question of 
which of the two evidence-based dietary approaches, gluten-free diet or low 
FODMAP diet, physicians should advise to IBS patients [ 59 ]. A consistent number 
of patients increasingly recognize an association between gut symptoms and/or 
fatigue and ingestion of wheat products, such as pasta and bread. An Australian 
survey of 1,184 IBS adults reported that 8 % avoid wheat or consume a gluten-free 
diet to relieve their symptoms [ 70 ]. 
 Even if a low FODMAP diet, being more restrictive, offers a higher chance of 
symptomatic response, a gluten-free diet could remove a specifi c pathogenic factor. 
To date, no consensus has been reached. A gluten-free diet might be used if the 
clinic is geared toward an exclusion diet followed by DBPC rechallenge, especially 
in patients with biomarkers suggesting gluten-related relevant pathogenic events: 
circulating antibodies to whole gliadin, high in vitro basophil activation, increased 
fecal eosinophil cationic protein and tryptase, and increased duodenal IEL density 
(>25/100 enterocytes) with or without eosinophil infi ltration. Non-responder sub-
jects should be tested with a low FODMAP diet. Alternatively, a low FODMAP diet 
might be used as the fi rst approach, and in those with insuffi cient response, gluten 
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could be removed as the second step. If an adequate response occurs, then non- 
wheat- based FODMAP intake can be cautiously increased [ 53 ]. 
 Conclusion 
 Emerging evidence argues with increasing insistence for the role of food intoler-
ance in the management of IBS symptoms. Food components should be consid-
ered not as etiological elements of IBS, but as symptom triggers. Thus, changes 
in dietary intake might allow consistent improvement in symptoms and quality 
of life even if they do not represent a cure and don’t infl uence the pathogenic 
mechanisms. To date, physicians are focusing on the role of a low FODMAP diet 
in symptom improvement in many patients suffering from IBS. The increasing 
evidence for this dietary approach supports the hypothesis that it should be the 
fi rst dietary modifi cation in patients suffering from IBS. However promising, this 
dietary approach still leaves many questions unanswered, including the evalua-
tion of possibly signifi cant nutritional concerns. This point must be stressed, and 
patients should be discouraged from undertaking a low FODMAP diet without 
adequate support from a dietitian. To further complicate the extended framework 
of IBS triggers, there are many other food components besides carbohydrates 
worthy of being studied. Among these, dietary fats might change visceral hyper-
sensitivity, whereas naturally occurring chemicals, widespread in foods, could 
interact with gut receptors or have direct actions on the enteric nervous system 
and mast cells. Finally, the role of wheat and gluten in IBS is far from being 
completely understood, and physicians should always consider the possible use 
of a sequential dietetic approach (low FODMAP/gluten-free diet). 
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